more agreements, page-5

BOS has huge potential but what is required is proof that the technology can be commercially applied in at least one application. I don't have a problem with concurrently researching multiple diverse applications SO LONG AS this approach is not spreading BOS's limited technical resources too thin and thereby delaying the development of key applications (eg, contact lenses). We really need significant progression in at least one application by the end of CY06 - revenue generation is a must for biotech companies who have a history of burning funds for years and years with little to show. BOS has the potential to break from the norm.

I have no doubt that once one application is successfully developed to market, unlimited opportunities will open up and the company will fly.